drug induced dyskinesia

Summary

Summary: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)

Top Publications

  1. ncbi Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease
    Mark S Baron
    Mov Disord 18:1208-9. 2003
  2. ncbi A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
    O Rascol
    Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France
    N Engl J Med 342:1484-91. 2000
  3. ncbi A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function
    M Lundblad
    Department of Physiological Sciences, Neurobiology Division, Wallenberg Neuroscience Centre, Lund University, S 223 62 Lund, Sweden
    Neurobiol Dis 16:110-23. 2004
  4. ncbi Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique Unite Mixte de Recherche 5541, Bordeaux Cedex, France
    Ann Neurol 57:17-26. 2005
  5. ncbi Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
  6. ncbi Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Neurol 2:382-92. 2006
  7. ncbi Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study
    Fabrizio Stocchi
    Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy
    Ann Neurol 68:18-27. 2010
  8. ncbi The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat
    E L Lane
    Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden
    Neurobiol Dis 22:334-45. 2006
  9. ncbi Nondopaminergic mechanisms in levodopa-induced dyskinesia
    Jonathan M Brotchie
    Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 20:919-31. 2005
  10. ncbi L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA
    M A Cenci
    Wallenberg Neuroscience Center, Institute of Physiology and Neuroscience, University of Lund, 223 62 Lund, Sweden
    Eur J Neurosci 10:2694-706. 1998

Detail Information

Publications202 found, 100 shown here

  1. ncbi Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease
    Mark S Baron
    Mov Disord 18:1208-9. 2003
  2. ncbi A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
    O Rascol
    Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France
    N Engl J Med 342:1484-91. 2000
    ..There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist...
  3. ncbi A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function
    M Lundblad
    Department of Physiological Sciences, Neurobiology Division, Wallenberg Neuroscience Centre, Lund University, S 223 62 Lund, Sweden
    Neurobiol Dis 16:110-23. 2004
    ..The mouse model of L-DOPA-induced dyskinesia will provide a useful tool to study the molecular determinants of this movement disorder in transgenic mice strains...
  4. ncbi Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique Unite Mixte de Recherche 5541, Bordeaux Cedex, France
    Ann Neurol 57:17-26. 2005
    ..Our data suggest that levodopa-induced dyskinesia results from increased dopamine D(1) receptor-mediated transmission at the level of the direct pathway...
  5. ncbi Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...
  6. ncbi Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Neurol 2:382-92. 2006
    ..The current challenge is to develop a long-acting oral formulation of levodopa that provides comparable anti-parkinsonian benefits without motor complications...
  7. ncbi Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study
    Fabrizio Stocchi
    Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy
    Ann Neurol 68:18-27. 2010
    ....
  8. ncbi The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat
    E L Lane
    Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden
    Neurobiol Dis 22:334-45. 2006
    ..In conclusion, robust and reproducible AIMs were evoked in rats with large grafts by blockade of monoamine reuptake. These AIMs may provide a new tool for assessing dyskinetic effects of neural grafting...
  9. ncbi Nondopaminergic mechanisms in levodopa-induced dyskinesia
    Jonathan M Brotchie
    Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 20:919-31. 2005
    ..SV2A, have been identified. This increased understanding has already delivered and will continue to define novel approaches to treatment that target both pre- and postsynaptic signaling molecules throughout the basal ganglia circuitry...
  10. ncbi L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA
    M A Cenci
    Wallenberg Neuroscience Center, Institute of Physiology and Neuroscience, University of Lund, 223 62 Lund, Sweden
    Eur J Neurosci 10:2694-706. 1998
    ..Due to its treatment-dependent expression, and strong correlation with the associated dyskinetic symptoms, striatal PDyn mRNA, in particular, may play a role in the mechanisms of behavioural sensitization brought about by the drug...
  11. ncbi Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates
    Celine Guigoni
    CNRS UMR 5227, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
    Neurobiol Dis 26:452-63. 2007
    ..Further experiments including parkinsonian monkeys chronically treated with L-dopa that show no dyskinesia and parkinsonian monkeys treated only once with L-dopa are now necessary to confirm our hypothesis...
  12. ncbi Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
    Erwan Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen, 33076 Bordeaux, France
    Nat Med 9:762-7. 2003
    ....
  13. ncbi Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
    E Bezard
    Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, , , 33076 Bordeaux Cedex, France
    Nat Rev Neurosci 2:577-88. 2001
    ..Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems...
  14. ncbi Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial
    A J Lees
    National Hospital for Neurology and Neurosurgery, London, UK
    Neurology 57:1687-94. 2001
    ..A slightly lower incidence of motor complications is achieved at the expense of significantly worse disability scores throughout the first years of therapy...
  15. ncbi Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats
    Manolo Carta
    Department of Exp Medical Science, Basal Ganglia Pathophysiology Unit, Lund University, Lund, Sweden
    J Neurochem 96:1718-27. 2006
    ..Individual differences in the central bioavailability of L-DOPA may provide a clue to the varying susceptibility to dyskinesia in Parkinson's disease...
  16. ncbi L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function
    Christian Winkler
    Department of Physiological Sciences, Neurobiology Division, Wallenberg Neuroscience Center, Lund University, BMC A11, S 221 84, Lund, Sweden
    Neurobiol Dis 10:165-86. 2002
    ....
  17. ncbi The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I
    P N van Harten
    Psychiatric Hospital Welterhof, Heerlen, Netherlands
    Schizophr Res 19:195-203. 1996
    ....
  18. ncbi Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
    Barbara Picconi
    Clinica Neurologica, Dipartimento di Neuroscienze, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Nat Neurosci 6:501-6. 2003
    ..These results indicate that abnormal information storage in corticostriatal synapses is linked with the development of L-DOPA-induced dyskinesia...
  19. ncbi ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice
    Nancy Pavon
    Instituto Cajal, Consejo Superior de Investigaciones Cientificas, Madrid, Spain
    Biol Psychiatry 59:64-74. 2006
    ..We have developed a model of L-DOPA-induced dyskinesias in mice that reproduces the main clinical features of dyskinesia in humans...
  20. ncbi Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys
    Carl Julien
    Molecular Endocrinology and Oncology Research Centre, Centre Hospitalier de l Université Laval Research Centre CHUL, Que, Canada
    Neurochem Int 48:404-14. 2006
    ..01). These results suggest that changes in brain fatty acid relative concentrations are associated with levodopa treatment in PD patients and in a non-human primate model of parkinsonism...
  21. ncbi Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
    Christoph U Correll
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Schneider Children s Hospital, Glen Oaks, NY 11004, USA
    Am J Psychiatry 161:414-25. 2004
    ..This hypothesis was examined in a systematic review of studies involving open or controlled treatment with any second-generation antipsychotic...
  22. ncbi Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease
    C S Lee
    Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, Vancouver, Canada
    Brain 123:1365-79. 2000
    ....
  23. ncbi Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study
    Diederik E Tenback
    Psychiatric Center Altrecht, Den Dolder, The Netherlands
    Compr Psychiatry 48:436-40. 2007
    ..The objective of the study was to examine if worsening of psychosis predicts the emergence of tardive dyskinesia (TD)...
  24. ncbi Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances
    Diederik E Tenback
    Psychiatric Center Altrecht, Den Dolder, The Netherlands
    Neuropsychopharmacology 31:1832-7. 2006
    ..This may suggest a shared, pandopaminergic pathological mechanism associated with schizophrenia itself, rather than only a medication effect...
  25. ncbi Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V
    Peter N van Harten
    Symfora Group Psychiatric Center, Amersfoort, The Netherlands
    J Clin Psychiatry 67:1920-7. 2006
    ..Do these patients remain at risk for TD or TDt and, consequently, should a switch to SGAs be considered? A longitudinal cohort study in patients on long-term antipsychotic treatment may answer this question...
  26. ncbi The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations
    Fabrizio Stocchi
    Department of Neurology, IRCCS San Raffaele Pisana, via della Pisana 235, 00163, Rome, Italy
    Expert Opin Pharmacother 7:1399-407. 2006
    ....
  27. ncbi Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype
    Bernard Lerer
    Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Int J Neuropsychopharmacol 8:411-25. 2005
    ..Together with other genetic variants associated with TD the findings could be used to assess risk in patients who are candidates for treatment with typical antipsychotic medications...
  28. ncbi "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease
    Roger Kurlan
    Department of Neurology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Neurology 64:923-4. 2005
  29. ncbi Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
    Olivier Rascol
    Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse, France
    Mov Disord 21:1844-50. 2006
    ..Early use of ropinirole postpones the onset of dyskinesias, but these benefits decline when levodopa therapy is started, with no evidence of a subsequent rapid "catch-up" or a persisting preventive effect...
  30. ncbi Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms
    J S Schneider
    Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, 521 JAH, Philadelphia, PA 19107, USA
    Brain Res 990:38-44. 2003
    ....
  31. ncbi Focus on lower risk of tardive dyskinesia with atypical antipsychotics
    Henry A Nasrallah
    Departments of Psychiatry, Neurology, and Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Ann Clin Psychiatry 18:57-62. 2006
    ..Identifying the risk factors for TD is important to minimize the risk of this potentially irreversible movement disorder in susceptible populations...
  32. ncbi Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study
    Diederik E Tenback
    Department of Psychiatry and Neuropsychology, Maastricht University, P O Box 616 DRT 10, 6200 MD Maastricht, The Netherlands
    Am J Psychiatry 163:1438-40. 2006
    ..This study examined whether extrapyramidal symptoms predict incidence of tardive dyskinesia 1 year later...
  33. ncbi The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease
    J P Larsen
    Department of Neurology, Rogaland Central Hospital, Stavanger, Norway
    Eur J Neurol 10:137-46. 2003
    ..In conclusion, entacapone given in combination with levodopa, has a good long-term safety profile and a sustained beneficial effect in patients with PD with motor fluctuations...
  34. ncbi Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique CNRS Unité Mixte de Recherche UMR 5541, Bordeaux Cedex, France
    Biol Psychiatry 61:836-44. 2007
    ....
  35. ncbi Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus)
    E C Maratos
    Neurodegenenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    Mov Disord 16:631-41. 2001
    ..These data suggest that in early Parkinson's disease, the use of ropinirole alone or in combination with a low-dose L-DOPA might delay the induction of dyskinesias while improving motor performance...
  36. ncbi Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease
    J D Oh
    Department of Psychology, Central Michigan University, Mount Pleasant, Michigan, USA
    Amino Acids 23:133-9. 2002
    ....
  37. ncbi Neuromotor dysfunction in early psychosis
    David Whitehorn
    Nova Scotia Early Psychosis Program, Dartmouth, Canada
    Ann Clin Psychiatry 14:113-21. 2002
    ..Atypical antipsychotic agents can alleviate psychosis without inducing EPSS. Preexisting EPSS may be corrected...
  38. ncbi Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)
    Eleni C Maratos
    Neurodegenenerative Disease Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College London, London SE1 1UL, United Kingdom
    Exp Neurol 179:90-102. 2003
    ....
  39. ncbi Pathological synaptic plasticity in the striatum: implications for Parkinson's disease
    Barbara Picconi
    Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma Tor Vergata and Fondazione Santa Lucia, I R C C S, Via di Tor Vergata 135, Roma, Italy
    Neurotoxicology 26:779-83. 2005
    ..The potential relevance of these findings in the control of motor function and in the pathogenesis both of Parkinson's disease and l-dopa-induced motor complications will be discussed...
  40. ncbi Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia
    R H Segman
    Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Mol Psychiatry 6:225-9. 2001
    ....
  41. ncbi Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia
    Zhi Jun Zhang
    Department of Psychiatry, Nanjing Brain Hospital and Nanjing Medical University, Nanjing, People s Republic of China
    Psychiatr Genet 13:187-92. 2003
    ....
  42. ncbi Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia
    Ronnen H Segman
    Biological Psychiatry Laboratory, Department of Psychiatry Hadassah, Hebrew University Medical Center, Jerusalem, Israel
    Biol Psychiatry 51:261-3. 2002
    ..We investigated the association of a T -->C variation in the cytochrome P 450 17alpha-hydroxylase gene with tardive dyskinesia in patients with chronic schizophrenia...
  43. ncbi Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning
    Celine Guigoni
    Laboratoire de Physiologie et Physiopathologie de la Signalization Cellulaire, CNRS UMR 5543, Universite Victor Segalen Bordeaux, 33076 Bordeaux Cedex, France
    Eur J Neurosci 22:283-7. 2005
    ..These data indicate that neither the extent nor the pattern of nigrostriatal lesioning are sufficient to explain the occurrence of levodopa-induced dyskinesia...
  44. ncbi L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations
    R K Pearce
    Neurodegenerative Diseases Research Centre, Hodgkin Building, Division of Pharmacology and Therapeutics, GKT School of Biomedical Sciences, King's College London, Guy's Campus, London Bridge, London SE1 1UL, UK
    Psychopharmacology (Berl) 156:402-9. 2001
    ..CONCLUSIONS: These results show for the first time that chronic oral L-dopa administration can provoke dyskinesias in primates independently of nigrostriatal damage, and that this effect is dose related...
  45. ncbi Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia
    V S Basile
    Neurogenetics Section, Clarke Institute of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
    Mol Psychiatry 6:230-4. 2001
    ..Further studies evaluating in tandem multiple candidate genes relevant for the serotonergic system are warranted to dissect the genetic basis of the complex TD phenotype...
  46. ncbi Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients
    D L Liao
    Department of Psychiatry, Executive Yuan Department of Health, Pali Psychiatric Hospital, Taipei, Taiwan, ROC
    Neuropsychobiology 44:95-8. 2001
    ..Our results are in line with a previous report, the results of which suggest that the presence of the DRD3(ser-gly) genotype may be a risk factor for the development of TD in patients treated with antipsychotics...
  47. ncbi [Prevention and treatment of fluctuations in patients with Parkinson's disease]
    H P Ludin
    Neurologische Praxis, St Gallen
    Praxis (Bern 1994) 95:2013-8. 2006
    ..This is a rather simple way to achieve a continuous dopaminergic stimulation. The same goal is achieved by direct application of levodopa-/carbidopa-gelsuspension (Duodopa) in the duodenum by the help of an electronic pump...
  48. ncbi A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease
    Masahiko Tomiyama
    Department of Neurological Science, Institute of Brain Science, Hirosaki University School of Medicine, Hirosaki 036 8562, Japan
    Neurosci Res 52:185-94. 2005
    ..These results suggest that pharmaceutical products that stimulate 5-HT1A receptors could prove useful in prevention of the development of L-DOPA-induced motor complications in patients with Parkinson's disease...
  49. ncbi L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction
    H Russmann
    Department of Neurology, HUG, Geneva, Switzerland
    Neurology 63:153-5. 2004
    ..03). These data support dopaminergic stimulation and striatal desensitization as major determinants of LID in PD...
  50. ncbi Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions
    Gurutz Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Guipuzcoa, Spain
    Mov Disord 19:743-54. 2004
    ..Some of the recent trials and possible reasons for their lack of success are critically analysed. Finally, some suggestions to avoid further failures and improve results are proposed...
  51. ncbi Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease
    V Mesnage
    centre d investigation clinique, Fédération de Neurologie and Inserm, Paris, France
    Clin Neuropharmacol 27:108-10. 2004
    ..In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability...
  52. ncbi Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s, and St Thomas School of Biomedical Sciences, King s College, London, UK
    Curr Opin Neurol 16:S3-7. 2003
    ..Most currently used dopamine agonists are selective for D2-like receptors, with only pergolide and apomorphine potentially interacting with D1 receptor populations...
  53. ncbi Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 5:677-87. 2006
    ..The current challenge is to develop a long-acting oral formulation of levodopa that provides clinical benefits but avoids motor complications...
  54. ncbi [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa]
    G Linazaroso
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian
    Neurologia 19:117-27. 2004
    ..Thus, this may have important implications for the discovery of new therapeutic strategies...
  55. ncbi Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia
    Mark Stacy
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Neuropharmacol 31:51-6. 2008
    ..In the long-term management of PD, treatment-associated dyskinesia often becomes sufficiently troublesome as to compromise the effective dosing of antiparkinsonian medication. More effective strategies for managing dyskinesia are needed...
  56. ncbi Rapid treatment of "wearing off" in Parkinson's disease
    David M Swope
    Department of Neurology, Loma Linda University, Loma Linda, California 92354, USA
    Neurology 62:S27-31. 2004
    ....
  57. ncbi [Levodopa for Parkinson's disease: What have we learned?]
    Carlos Juri C
    Departamento de Neurologia, Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile
    Rev Med Chil 134:893-901. 2006
    ..The new available presentations of levodopa are also reviewed. The implications of these advances for the treatment of this disease are commented...
  58. ncbi The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis
    Harold D Foster
    Department of Geography, University of Vic, PO Box 3050, Victoria, BC, Canada V8W 3P5
    Med Hypotheses 62:177-81. 2004
    ..A literature review suggests that all three corollaries are probably correct...
  59. ncbi Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report
    Ron L Alterman
    Department of Neurosurgery, Hyman Newman Institute for Neurology and Neurosurgery, Yarmon Center for Parkinson Disease, Beth Israel Medical Center, New York, USA
    Neurosurg Focus 17:E6. 2004
    ..The 3389 lead may provide inadequate coverage of the subthalamic region for some patients...
  60. ncbi A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy
    Gulcin Benbir
    Department of Neurology, University of Istanbul, Cerrahpasa Faculty of Medicine, Istanbul 34098, Turkey
    Clin Neurol Neurosurg 108:726-32. 2006
    ..Although levodopa (LD) is the gold standard therapy for symptomatic treatment of Parkinson's disease (PD), the chronic use of LD leads to the development of motor complications in almost all patients...
  61. ncbi Pathophysiology of motor fluctuations in Parkinson's disease
    Katherine Widnell
    Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin, USA
    Mov Disord 20:S17-22. 2005
    ..We discuss the theory of continuous dopaminergic stimulation and its implications for the management of motor fluctuations in patients with advanced and early PD...
  62. ncbi Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study
    Mayumi Kitagawa
    Department of Neurology, Sapporo Azabu Neurosurgical Hospital, Sapporo, Japan
    Intern Med 44:939-43. 2005
    ..To investigate the efficacy and the rate of adverse events of chronic low-dose levodopa-carbidopa therapy in Japanese patients with Parkinson's disease (PD)...
  63. ncbi [The role of dopaminagonists in the treatment of Parkinson's disease]
    G Ransmayr
    Abteilung für Neurologie und Psychiatrie, Allgemeines Krankenhaus der Stadt Linz
    Praxis (Bern 1994) 94:1633-8. 2005
    ..The "new" dopaminagonists pergolide, cabergoline, ropinirole and pramipexole tend to be more effective than bromocriptine. Due to side-effects dopamine agonists are mainly used in subjects younger than 70 to 75 years...
  64. ncbi Other pharmacological treatments for motor complications and dyskinesias
    Cheryl Waters
    Division of Movement Disorders, Department of Neurology, Columbia University, 710 West 168th Street, New York, NY 10032, USA
    Mov Disord 20:S38-44. 2005
    ..Patients may also suffer from dyskinesias. Dyskinesias can be treated with small doses of liquefied levodopa-carbidopa, amantadine, and clozapine, an atypical neuroleptic...
  65. ncbi [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]
    Silke Wedekind
    MMW Fortschr Med 147:10. 2005
  66. pmc Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
    Bhomraj Thanvi
    Department of Integrated Medicine, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK
    Postgrad Med J 83:384-8. 2007
    ..LID can adversely affect the quality of life and increase the cost of healthcare...
  67. ncbi Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists
    Christelle Monville
    Cardiff University, School of Biosciences, Museum Avenue, Cardiff CF10 3US, UK
    Brain Res Bull 68:16-23. 2005
    ..g. using grafts while blocking the unwanted adverse effects of the drugs...
  68. ncbi A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease
    Tom H Johnston
    Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
    Exp Neurol 191:243-50. 2005
    ..These observations highlight the association between potential anti-dyskinetic action and a selective reduction in l-DOPA-induced vertical activity in the reserpine-treated rat...
  69. ncbi Role of the pharmacist in the effective management of wearing-off in Parkinson's disease
    William Simonson
    Commission for Certification in Geriatric Pharmacy
    Ann Pharmacother 41:1842-9. 2007
    ..To evaluate the role of the practicing pharmacist in the identification and current treatment of the levodopa wearing-off phenomenon experienced by patients with Parkinson's disease (PD) who are receiving chronic levodopa therapy...
  70. ncbi l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
    Barbara Picconi
    Laboratorio di Neurofisiologia, Fondazione Santa Lucia, IRCCS c o CERC, Rome, Italy
    Neurobiol Dis 29:327-35. 2008
    ....
  71. ncbi The management approaches to dyskinesia vary from country to country
    Dirk Woitalla
    Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
    Neuroepidemiology 29:163-9. 2007
    ..6% of UK physicians were dissatisfied with current treatment strategies for dyskinesia. Regardless of geographical location, physicians were dissatisfied with the current treatment strategies for dyskinesia...
  72. ncbi Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications
    Vesna Sossi
    University of British Columbia, Vancouver, Canada
    Brain 129:1050-8. 2006
    ..These results provide one possible explanation for the age-dependent occurrence of complications and support the existence of a pre-synaptic contribution to the occurrence of motor complications...
  73. ncbi Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Mov Disord 19:1256-8. 2004
    ..Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders...
  74. ncbi Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    Brain 127:888-99. 2004
    ..The model supports the idea that presynaptic mechanisms play a key role in both short-duration and long-duration responses encountered in Parkinson's disease. Dyskinesias may also be explained by the same mechanisms...
  75. pmc Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study
    R Katzenschlager
    Reta Lila Weston Institute of Neurological Studies, University College London, National Hospital for Neurology and Neurosurgery, UK
    J Neurol Neurosurg Psychiatry 75:295-7. 2004
    ..Drug induced dyskinesias remain a challenging problem in the long term management of Parkinson's disease (PD). We have assessed the effect of quetiapine on dyskinesias in a double blind placebo controlled cross over study...
  76. ncbi High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias
    S Cristina
    Parkinson s Disease and Movement Disorders Unit, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, C Mondino, University of Pavia, Italy
    Clin Neuropharmacol 26:146-50. 2003
    ....
  77. ncbi Dyskinesia: L-dopa-induced and tardive dyskinesia
    O Rascol
    Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U 455, Toulouse University-Hospital, 37 allees J. Guesde, 31073 Toulouse Cedex, France
    Clin Neuropharmacol 24:313-23. 2001
    ....
  78. ncbi L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism
    R Kaiser
    Institute of Clinical Pharmacology, Charite, Humboldt Universitat zu Berlin, Germany
    Neurology 60:1750-5. 2003
    ..To assess whether polymorphisms in the dopamine receptor genes and in the dopamine transporter gene (DAT ) are predictors of adverse effects of L -dopa...
  79. ncbi Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up
    Petr Kanovsky
    1st Department of Neurology, Masaryk University, St Anne Hospital, Brno, Czech Republic
    Mov Disord 17:188-91. 2002
    ..Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up...
  80. ncbi Pergolide in the treatment of patients with early and advanced Parkinson's disease
    Ubaldo Bonuccelli
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Clin Neuropharmacol 25:1-10. 2002
    ..The side-effect profile of pergolide is similar to that of other dopamine agonists, and complications such as sleep attack and serosal fibrosis have been rarely reported...
  81. ncbi Long-term outcome of quetiapine use for psychosis among Parkinsonian patients
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Mov Disord 18:510-4. 2003
    ..6; 95% CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07)...
  82. ncbi [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation]
    A Destee
    Clinique Neurologique, EA 2683 MENRT, Service de Pharmacologie Clinique, EA 1046 MNERT, CHU Lille
    Rev Neurol (Paris) 158:S69-82. 2002
    ..Dopaminergic agonists provide a promising alternative. Another possibility is to modulate the peripheral kinetics of levodopa as soon as it is introduced using catechol-O-methyl transferase inhibitors...
  83. ncbi Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments
    Elmyra V Encarnacion
    Department of Neurology, Texas A and M Health Sciences Center, Scott and White National Parkinson Foundation Plummer Movement Disorders Center, Temple, TX, USA
    Eur Neurol 60:57-66. 2008
    ..Several new compounds that may provide an antidyskinetic effect are also under investigation...
  84. ncbi The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches
    D Merims
    Department of Neurology, Rabin Medical Center, Belinson Campus, Petah Tikva
    Neurol Neurochir Pol 35:65-8. 2001
    ..Indeed, NMDA receptor antagonists such as amantadine and dextrometorphan can reduce such dyskinesias. We tested the efficacy of riluzole, an inhibitor of glutamatergic transmission in the inhibition of levodopa-induced dyskinesias...
  85. ncbi Initial agonist treatment of Parkinson disease: a critique
    Roger L Albin
    Department of Neurology, Geriatric Research, Education, and Clinical Center, Ann Arbor VAMC, University of Michigan, Ann Arbor, USA
    Neurology 60:390-4. 2003
    ..The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD...
  86. ncbi Should levodopa be used anymore?
    Diederik Zegers de Beyl
    Service de Neurologie, Hopital Erasme, U L B, Bruxelles, Belgium
    Acta Neurol Belg 102:163-6. 2002
    ..Prospective clinical data do not support this idea with the present drugs. Levodopa remains the most useful treatment and most clinicians believe that it is wise to associate early on levodopa with one of the dopamine agonists...
  87. ncbi [Pergolide: a useful agonist for the treatment of Parkinson disease]
    A M Bonnet
    Federation de Neurologie, INSERM U289, Hopital Pitie Salpetriere, 47 bd de l Hopital, 75651 Paris
    Rev Neurol (Paris) 158:744-5. 2002
    ..In this group of patients with most serious motor disability, it has been possible to improve dyskinesia and fluctuations with a relatively important dosage of pergolide and without increase of levodopa dosage...
  88. ncbi Are there clinically significant differences between dopamine agonists
    Fabrizio Stocchi
    Institute of Neurology IRCCS Neuromed Is, University La Sapienza, Rome, Italy
    Adv Neurol 91:259-66. 2003
  89. ncbi Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists
    Tomoyoshi Kondo
    Department of Neurology, Wakayama Medical University, 811 1 Kimiidera, Wakayama 641 0035, Japan
    J Neurol 249:II25-9. 2002
    ..Although the patient's conditions should be considered in the selsction of a drug, DA agonist therapy is recommended as the initial therapy for Parkinson's disease...
  90. ncbi Striatal synaptic plasticity: implications for motor learning and Parkinson's disease
    Antonio Pisani
    Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma Tor Vergata and Fondazione Santa Lucia, I R C C S, Roma, Italy
    Mov Disord 20:395-402. 2005
    ..The potential relevance of these findings in the control of motor function and in the pathogenesis both of PD and L-dopa-induced motor complications will be discussed...
  91. ncbi New drugs in the future treatment of Parkinson's disease
    Ruth Djaldetti
    Chairman Department of Neurology, Rabin Medical Center, Beilinson Campus, 49100 Petach Tiqva, Israel
    J Neurol 249:II30-5. 2002
    ....
  92. ncbi COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10028, USA
    Neurology 62:S72-81. 2004
    ..This article considers the possibility that combining levodopa with entacapone may prevent or reverse motor complications...
  93. ncbi Continuous dopaminergic stimulation in early and advanced Parkinson's disease
    Fabrizio Stocchi
    Department of Neuroscience and IRCCS Neuromed Pozzilli IS, University La Sapienza, Rome, Italy
    Neurology 62:S56-63. 2004
    ..Therefore, the development of a simple treatment regimen using an oral formulation of levodopa to provide a more continuous dopaminergic stimulation will represent a significant advance in antiparkinsonian pharmacotherapy...
  94. ncbi Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia
    Paula Ravenscroft
    School of Biological Sciences, University of Manchester, Manchester M13 9PT, UK
    Exp Neurol 185:36-46. 2004
    ....
  95. ncbi Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease
    Hiroshi Kase
    Kyowa Hakko Kogyo Co Ltd, Tokyo, Japan
    Neurology 61:S97-100. 2003
    ..The selective A2A antagonist should provide a novel nondopaminergic approach to PD therapy...
  96. ncbi The art of treating Parkinson disease in the older patient
    Daniel Kam Yin Chan
    University of New South Wales, Aged Care and Rehabilitation, Bankstown Hospital, New South Wales
    Aust Fam Physician 32:927-31. 2003
    ..Parkinson disease (PD) is a neurodegenerative disorder that increases sharply after the sixth decade. There are many disorders in the elderly that exhibit some parkinsonian signs that can be confused with PD...
  97. ncbi Agonists versus levodopa in PD: the thrilla of whitha
    Erwin B Montgomery
    Neurology 61:1462; author reply 1462-3. 2003
  98. ncbi Clinical strategies to prevent and delay motor complications
    Paolo Barone
    Department of Neurological Sciences, University Federico II, Naples, Italy
    Neurology 61:S12-6. 2003
    ....
  99. ncbi Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD
    Robert A Hauser
    Department of Neurology, University of South Florida, and Tampa General Healthcare, 33606, USA
    Neurology 61:297-303. 2003
    ..To evaluate the safety and efficacy of the adenosine A(2A) receptor antagonist istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with both motor fluctuations and peak-dose dyskinesias...
  100. ncbi Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study
    P Del Dotto
    Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56100 Pisa, Italy
    Mov Disord 16:515-20. 2001
    ..This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations...
  101. ncbi Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia
    A Beyeler
    Universite de Bordeaux, 33076 Bordeaux Cedex, France Centre National de la Recherche Scientifique Unité Mixte de Recherche 5227, 33076 Bordeaux Cedex, France
    Neuroscience 169:158-70. 2010
    ..These results suggest that oral dyskinesia induced by 5-HT(2C) agonists are not restricted to aberrant signalling in the orofacial motor circuit and demonstrate discrete modifications in associative territories...

Research Grants65

  1. MOTOR FUNCTIONS AND FIBER CONNECTIONS OF PALLIDUM
    SAMUEL LILES; Fiscal Year: 1990
    ..Autoradiographic tracing methods will be used as a control to study the corticostriatal projection in these experiments...
  2. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. [unreadable] [unreadable] [unreadable] [unreadable]..
  3. GABA AGONIST THERAPY IN TARDIVE DYSKINESIA
    Carol Tamminga; Fiscal Year: 1999
    ..We propose that these studies will help advance our overall goals of understanding-the mechanism of -TD and developing treatments for-the disorder. ..
  4. DYNAMICS OF PALLIDAL ACTIVITY IN PARKINSONS DISEASE
    KAREN SIGVARDT; Fiscal Year: 2003
    ....
  5. DOUBLE-BLIND CONTROLLED TRIAL OF NIGRAL GRAFTING IN PD
    C Olanow; Fiscal Year: 2003
    ..abstract_text> ..
  6. NEUROLEPTIC-INDUCED MOVEMENT DISORDERS IN OLDER PATIENTS
    Dilip Jeste; Fiscal Year: 2003
    ..We believe that our findings will have major therapeutic implications for the use of antipsychotics, particularly in older patients. ..
  7. DVD Consent for Research in Older Schizophrenia Patients
    Dilip Jeste; Fiscal Year: 2008
    ..The DVD-based consent is not intended to supplant, but rather to supplement, the researcher-participant in-person interaction involved in consent process. ..
  8. Metabolic Effects of Newer Antipsychotics in Older Pts
    Dilip Jeste; Fiscal Year: 2009
    ..abstract_text> ..
  9. LATE ONSET SCHIZOPHRENIA--A NEUROPSYCHIATRIC STUDY
    Dilip Jeste; Fiscal Year: 2002
    ..g., MRI quantitative analysis, outcome and functioning measures) to the new questions being asked. Our studies should have a major impact on the understanding of schizophrenia and aging. ..
  10. CENTER FOR RESEARCH IN OLDER PEOPLE WITH PSYCHOSES
    Dilip Jeste; Fiscal Year: 2006
    ....
  11. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    Scott Woods; Fiscal Year: 2003
    ..Thus, we are proposing to add these aims. ..
  12. Enhancing the Prospective Prediction of Psychosis
    Scott Woods; Fiscal Year: 2007
    ..Each site has provefi its ability to recruit prodromal patients in a previous collaboration. ..
  13. TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC
    Scott Woods; Fiscal Year: 2004
    ..The existence of a previous sample at the same site provides a useful additional comparison group. Methods including sample ascertainment and TD assessment are closely modeled after the original work. ..
  14. LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS
    John Nutt; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  15. Nicotine and Cognition in Parkinsonism
    Jay Schneider; Fiscal Year: 2008
    ..Information obtained from these studies will hopefully lead to more efficient design of nicotinic therapeutics for patients with a variety of cognitive disorders. ..
  16. GM1 Ganglioside Effects on Parkinson's Disease
    Jay Schneider; Fiscal Year: 2007
    ..Working hypothesis: Long-term GM1 use will stabilize symptoms or slow the progression of symptoms in PD patients and this may be accompanied by reduced loss of striatal DA terminals over time. [unreadable] [unreadable]..
  17. Genetic Polymorphism of a Schizophrenia Endophenotype
    Ikwunga Wonodi; Fiscal Year: 2007
    ..Deciphering the genetic mechanisms of prefrontal dopamine dysfunction in schizophrenia would advance our understanding of the pathophysiology of schizophrenia and may help identify novel treatments. [unreadable] [unreadable] [unreadable]..
  18. ANTIPSYCHOTIC TREATMENT RESPONSE
    Del Miller; Fiscal Year: 2004
    ..This award will also serve as a mechanism by which the candidate can establish professional collaborative relationships with his mentors and provide him with the background for ongoing research leading to an independent research career. ..
  19. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  20. MOTOR/COGNITIVE ASYMMETRY IN OLDER PSYCHOTIC PATIENTS
    James Lohr; Fiscal Year: 2002
    ..We hope these studies will provide insights into the localization of pathology in schizophrenia and bipolar disorder, as well as their relationship to each other. ..
  21. Multiple Factors Affecting Placebo Response in PD
    Christopher Goetz; Fiscal Year: 2004
    ..Defining these determinant influences will help enhance placebo responses in clinical practice and control them in clinical trials. ..
  22. Apathy in Alzheimer's Disease Methylphenidate Trial
    Paul B Rosenberg; Fiscal Year: 2010
    ..This study aims to develop a new treatment for apathy in AD that could decrease its debilitating consequences and reduce patients'dependency on caregivers, providing well-deserved relief to patients and their loved ones. ..
  23. Evaluating Striatal Function in a Murine HD Model
    Roger Albin; Fiscal Year: 2007
    ..Validation of these methods will provide new and useful behavioral tools for evaluating murine disease models. [unreadable] [unreadable] [unreadable]..
  24. Diagnostic Error in Dystonia
    Caroline M Tanner; Fiscal Year: 2010
    ..If successful, this approach could be applied in other medical care settings, as well as for other rare disorders, to improve medical care and efficiency, and reduce suffering. ..
  25. A1/A2A Receptors and Caffeine Psychostimulation
    Jiang Fan Chen; Fiscal Year: 2009
    ..abstract_text> ..
  26. Transport of TNFalpha across the BBB
    Weihong Pan; Fiscal Year: 2008
    ..These transporters could be novel drug targets and therefore provide promising therapeutic potential. [unreadable] [unreadable]..
  27. Adapting a Physical Activity Intervention for Schizophrenia
    Laurie Lindamer; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  28. Aberrant Synaptic Plasticity: Impact of Dopamine on Graft Outcome
    Kathy Steece Collier; Fiscal Year: 2008
    ..abstract_text> ..
  29. Bioinformatics & identification of cis elements for dopamine gene expression
    Jiang Fan Chen; Fiscal Year: 2008
    ....
  30. 2-Way Pagers to Improve Schizophrenia Medication Adherence
    Delbert Robinson; Fiscal Year: 2008
    ..Results of this R34 intervention development project will provide a blueprint for the optimal design of future fully powered efficacy and effectiveness trials ..
  31. PREVENTING MORBIDITY IN FIRST EPISODE SCHIZOPHRENIA
    Delbert Robinson; Fiscal Year: 2008
    ..The findings will provided guidance to clinicians in the selection of the best medication for patients experiencing a first episode of illness, who have no prior treatment history to guide this choice. ..
  32. Long-term Ambulatory Gait Monitor for Parkinson's Disease
    Steven Moore; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  33. Electrocorticographic Study of Categorical Phoneme Perception in the Human Tempor
    Edward Chang; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  34. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2008
    ..This will be an important step for improving the lives of people with schizophrenia. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  35. Addiction and Subsequent Schizophrenia: A Link?
    Serge Sevy; Fiscal Year: 2008
    ..abstract_text> ..
  36. OLFACTION IN MULTIPLE SCLEROSIS
    RICHARD DOTY; Fiscal Year: 2001
    ....
  37. PANDAS and Strep Infection: Are they Linked?
    Roger Kurlan; Fiscal Year: 2004
    ..Disproving the PANDAS hypothesis would prevent the use of expensive and potentially dangerous therapies (e.g., plasma exchange, immune globulin, antibiotics) that have been proposed for PANDAS patients. ..
  38. TWINS AND RISK OF PD: A CLINICAL AND IMAGING STUDY
    Caroline Tanner; Fiscal Year: 2004
    ..This in turn could help set the research agenda on the cause of Parkinson's disease for years to come. ..
  39. Treating Agitation/Psychosis in Dementia/Parkinsonism
    Roger Kurlan; Fiscal Year: 2004
    ..This study will provide important information regarding the optimal treatment of psychosis and agitation for patients with the commonly encountered combination of primary dementia and parkinsonism. ..
  40. GENE-ENVIRONMENT INTERACTION IN ETIOLOGY OF DRUG ABUSE
    Stephan Arndt; Fiscal Year: 2008
    ..Results will provide information useful to both drug prevention (by identifying new early risk factors for adult drug abuse) and treatment (by identifying cognitive deficits which decrease treatment efficiency). ..
  41. PESTICIDES AND RISK IN THE AGRICUTURAL HEALTH STUDY
    Caroline Tanner; Fiscal Year: 2004
    ..The investigators believe that this work could provide a critical and dramatic next step in furthering our knowledge of environmental determinants of PD, and thereby take us closer to our goal of finding its cause(s). ..
  42. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    Stephen Marder; Fiscal Year: 2003
    ..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
  43. Nocardia: A Novel Environmental Agent For Parkinsonism?
    Peter LeWitt; Fiscal Year: 2003
    ..These outcomes will be significant because they should add to our understanding of the neurodegenerative process in PD, and could lead to improved means of diagnosis and treatment for individuals with this disorder. ..
  44. MIDCAREER INVESTIGATOR AWARD--PATIENT ORIENTED RESEARCH
    Karl Kieburtz; Fiscal Year: 2003
    ..abstract_text> ..
  45. Cardiac-Related Mortality with Atypical Antipsychotics
    DEANNA KELLY; Fiscal Year: 2005
    ..This study is important as data on long-term health outcomes with atypical antipsychotics is lacking from the literature. ..
  46. AGING AND THE COMPLEXITY OF VISUAL-MOTOR BEHAVIOR
    Karl Newell; Fiscal Year: 2005
    ..abstract_text> ..
  47. ADENOSINE /DOPAMINE INTERACTIONS IN A2A RECEPTOR KO MICE
    Jiang Fan Chen; Fiscal Year: 2002
    ..abstract_text> ..
  48. Transport of neurotrophic cytokines after spinal cord injury
    Weihong Pan; Fiscal Year: 2007
    ..Understanding the mechanisms of cytokine transport at this regulatory interface would help in the design of new approaches to treat SCI. ..
  49. NOVEL ANTIPSYCHOTICS AND STEREOTYPED MOVEMENT DISORDER
    Karl Newell; Fiscal Year: 2007
    ..of adaptive, goaloriented actions? And (4) Are there differences between the short and long term effects of atypical antipsychotics on aberrant behavior, abnormal movements, and goal-oriented motor task performance? ..
  50. Treatment Response to Rehabilitation in Schizophrenia
    Matthew Kurtz; Fiscal Year: 2002
    ..abstract_text> ..
  51. POSTMENOPAUSAL ESTROGEN INFLUENCES ON OLFACTION
    RICHARD DOTY; Fiscal Year: 2005
    ..Third, it would lead to testable hypotheses regarding the role of reproductive hormones, and their underlying mechanisms, in the maintenance of normal olfactory function. ..
  52. Southeastern Michigan Parkinson's Disease Program
    Peter LeWitt; Fiscal Year: 2006
    ..This application also discusses concepts for three pharmacological agents that could be investigated in pilot studies and, if promising, in multicenter clinical trials for assessing neuroprotection. ..
  53. Changing from Conventional to Risperidone Decanoate
    Nancy Covell; Fiscal Year: 2005
    ..Subjects will be interviewed with quantitative instruments at baseline and at follow-up intervals for 1 year. ..
  54. Therapy for self-injurious behavior in autism
    George Wagner; Fiscal Year: 2003
    ..In addition, based on this new model, the possible beneficial effects of risperidone, an antagonist of these transmitter systems, will be explored. ..
  55. Epidemiology of Dystonia in a Multi-Ethnic Population
    Caroline Tanner; Fiscal Year: 2009
    ..In addition, this cohort will provide a rich resource for future investigations including family studies, genetic analyses and further investigations of environmental risk factors. ..
  56. Skin Pigmentation and Parkinson's Disease Risk
    Caroline Tanner; Fiscal Year: 2003
    ..This could be an enormous breakthrough in our understanding of factors that influence the risk (and perhaps even the cause) of Parkinson's disease, and could lead to new strategies for disease prevention. ..
  57. Genetics of Early-Onset Depression
    William Lawson; Fiscal Year: 2008
    ..abstract_text> ..
  58. Ethnicity and the Diagnosis of Affective Illness
    William Lawson; Fiscal Year: 2008
    ..The final objective is to determine whether Latinos are at risk for similar problems in diagnostic assessments and treatment assignment. ..
  59. OLFACTION IN EPILEPSY
    RICHARD DOTY; Fiscal Year: 2004
    ..In addition to providing a better understanding of the influences of TLE and TLR on human olfactory function, this work may lead to the development of a simple and inexpensive non-invasive means for better establishing TLE seizure loci. ..
  60. Long-Term Olanzapine Treatment in children with Autism
    Richard Malone; Fiscal Year: 2008
    ..Phase 2 is a long-term (6 months) maintenance study of olanzapine responders who continue on open-labeled treatment. Phase 3 is a naturalistic follow-up of subjects. Multiple measures and raters are employed. ..
  61. COLLABORATIVE GENOMIC STUDY OF BIPOLAR DISORDER
    William Lawson; Fiscal Year: 2007
    ..Analysis of the existing sib pair families plus this large set of cases and controls should permit the confirmation of several vulnerability genes during this grant period. ..
  62. BRAIN SEROTONIN TRANSPORTER IN ECSTASY AND MDA USERS
    Stephen Kish; Fiscal Year: 2007
    ..More broadly, our data will help define the contribution of different neuroanatomical components of the brain serotonin system to human behavior. ..
  63. Psychopharmacology of Autism and related Disorders
    David Posey; Fiscal Year: 2007
    ..Towards the later years of the award, the candidate will have performed additional studies and applied for independent research funding. ..
  64. Controlled Study of Olanzapine in Children with Autism
    Richard Malone; Fiscal Year: 2005
    ..Abstract Not Provided ..